title: Clinical status of duplex RNA.
abstract: Double-stranded RNA has become a ubiquitous tool for inhibition of gene expression in the laboratory. If similar success could be achieved in vivo, duplex RNA might provide a new class of therapeutics capable of treating a broad spectrum of disease. Chemists and biologists developing duplex RNA as a drug have made progress but continue to face challenges. This review presents the current status of duplex RNA in the clinic and comments on future prospects for the approach.
authors.affiliation: Departments of Pharmacology and Biochemistry, UT Southwestern Medical Center at Dallas, 6001 Forest Park Road, Dallas, TX 75390, USA.
authors.forename: Jonathan K
authors.initials: JK
authors.lastname: Watts
authors.forename: David R
authors.initials: DR
authors.lastname: Corey
mesh_terms: D000818:Animals; D006801:Humans; D051379:Mice; D053758:Nanoparticles; D012330:RNA, Double-Stranded / Q000737:chemistry* / Q000494:pharmacology; D034741:RNA, Small Interfering; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
chemical_list: D012330:RNA, Double-Stranded; D034741:RNA, Small Interfering; D042461:Vascular Endothelial Growth Factor A
references.citation: Science. 1999 Sep 10;285(5434):1733-7
references.pmid: 10481009
references.citation: Nature. 2009 Jan 22;457(7228):426-33
references.pmid: 19158789
references.citation: Gene Ther. 2006 Aug;13(16):1222-34
references.pmid: 16625243
references.citation: Nature. 2004 Nov 11;432(7014):173-8
references.pmid: 15538359
references.citation: Nucleic Acids Res. 2010 Jan;38(1):1-16
references.pmid: 19843612
references.citation: J Clin Invest. 2007 Dec;117(12):3615-22
references.pmid: 18060019
references.citation: Nature. 2009 Jan 22;457(7228):396-404
references.pmid: 19158785
references.citation: Antiviral Res. 2008 Mar;77(3):225-31
references.pmid: 18242722
references.citation: Mol Cell Biol. 2002 Apr;22(7):2283-93
references.pmid: 11884613
references.citation: Nat Rev Drug Discov. 2010 Jan;9(1):57-67
references.pmid: 20043028
references.citation: Nature. 2008 Apr 3;452(7187):591-7
references.pmid: 18368052
references.citation: J Clin Invest. 2009 Mar;119(3):661-73
references.pmid: 19229107
references.citation: Oligonucleotides. 2009 Jun;19(2):89-102
references.pmid: 19441890
references.citation: Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21
references.pmid: 17379663
references.citation: Nature. 2001 May 24;411(6836):494-8
references.pmid: 11373684
references.citation: Angew Chem Int Ed Engl. 2009;48(8):1378-98
references.pmid: 19153977
references.citation: Hum Gene Ther. 2008 Feb;19(2):111-24
references.pmid: 18230025
references.citation: Nature. 1998 Feb 19;391(6669):806-11
references.pmid: 9486653
references.citation: Nat Rev Drug Discov. 2007 Jun;6(6):443-53
references.pmid: 17541417
references.citation: Nature. 2010 Apr 15;464(7291):1067-70
references.pmid: 20305636
references.citation: EMBO Mol Med. 2009 Jun;1(3):142-51
references.pmid: 20049714
references.citation: Bioorg Med Chem Lett. 2004 Mar 8;14(5):1139-43
references.pmid: 14980652
references.citation: Antimicrob Agents Chemother. 2009 Sep;53(9):3952-62
references.pmid: 19506055
references.citation: Drug Discov Today. 2008 Oct;13(19-20):842-55
references.pmid: 18614389
references.citation: Nat Rev Drug Discov. 2005 Sep;4(9):711-2
references.pmid: 16178119
references.citation: Nature. 2009 Jan 22;457(7228):405-12
references.pmid: 19158786
references.citation: Mol Ther. 2010 Feb;18(2):442-6
references.pmid: 19935778
references.citation: Cancer Res. 2008 Dec 1;68(23):9788-98
references.pmid: 19047158